🇺🇸 AB1010 in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 10
Most-reported reactions
- Acute Kidney Injury — 1 report (10%)
- Allergic Granulomatous Angiitis — 1 report (10%)
- Asthenia — 1 report (10%)
- Cardiac Failure Chronic — 1 report (10%)
- Condition Aggravated — 1 report (10%)
- Dyspnoea — 1 report (10%)
- Ejection Fraction Decreased — 1 report (10%)
- Myeloma Cast Nephropathy — 1 report (10%)
- N-Terminal Prohormone Brain Natriuretic Peptide Increased — 1 report (10%)
- Phlebitis — 1 report (10%)
AB1010 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is AB1010 approved in United States?
AB1010 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for AB1010 in United States?
AB Science is the originator. The local marketing authorisation holder may differ — check the official source linked above.